Takeda Pharmaceutical (TAK) said Wednesday its board approved further restructuring steps, including cutting corporate functions, simplifying processes with technology, and reorganizing leadership.

The company said it expects the plan to generate more than 200 billion yen ($1.26 billion) in annual savings by fiscal 2028, which it said will help cover costs tied to upcoming drug launches, including oveporexton, rusfertide and zasocitinib, as well as pipeline development and technology spending.

Takeda estimates restructuring charges of about 150 billion yen in fiscal 2026, with lower costs expected in the following two years, the company said.

It added that the measures will not have a material impact on its fiscal 2025 outlook.